Malaria Vaccine Reaching New Heights in Africa

by Dr. Reeja Tharu on  December 20, 2012 at 11:06 AM Health Watch   - G J E 4
Clinical trials for the malaria vaccine held recently have revealed that the vaccine RTS,S is capable of protecting infants in Africa against malaria.
Malaria Vaccine Reaching New Heights in Africa
Malaria Vaccine Reaching New Heights in Africa

The results from the phase III trials, first released in Cape Town, South Africa gives a new lease of hope to the people of the 'dark continent' in their fight against the deadly disease which kills millions of people each year, particularly pregnant women and infants.

During the study, infants were first vaccinated against clinical and severe malaria between the ages of 6 - 12 weeks. This was followed by two more doses. Upon a 12-month follow-up, the success rate was estimated to be between 31 and 33 per cent.

It is estimated that 1,700 children participated in the trial and the project is expected to save many lives, especially those of Tanzanian children who are constantly exposed to the killer disease. Follow-up in Phase III trials is expected to continue to provide more data. Nearly 86 percent of the trial participants used insecticide-treated bed nets which showed that RTS,S provided protection in addition to that provided by other existing malaria control interventions.

Despite the recent significant progress in the treatment of malaria, the disease still wipes out 655,000 people - mainly children below five years - in sub - Saharan Africa.

Apparently, last year, the efficacy observed with RTS,S in children aged 5-17 months against clinical and severe malaria was 56 per cent. This difference has prompted the scientists involved in the project to analyze more data available from the trials to determine the factors that influence the efficacy of the vaccine against malaria.

The good news is that it has been observed that infants can be administered this vaccine alongside the regular childhood vaccines. More information is expected by the end of 2014.

Eleven research centers are conducting these trials along with GlaxoSmithKline (GSK) and the PATH Malaria Vaccine Initiative (MVI), funded by the Bill & Melinda Gates Foundation.

According to the 'New England Journal of Medicine' if the required regulatory approvals are obtained and public health information is considered satisfactory, the WHO has suggested that a policy recommendation for the RTS,S malaria vaccine candidate would be possible by 2015. This would enable decisions to be made regarding the wide -spread use of the vaccine, along with other malaria-control methods, across Africa.

The results of the study have been published in the New England Journal of Medicine (online).

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

View All